Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension

ABSTRACT Objective: Most patients with severe hypertension are at high risk for cardiovascular events and require prompt blood pressure (BP)-lowering and combination therapy to achieve BP goals. This study evaluated the therapeutic efficacy and tolerability of initial treatment with the combination...

Full description

Saved in:
Bibliographic Details
Published in:Current medical research and opinion 2008-08, Vol.24 (8), p.2303-2311
Main Authors: Calhoun, David A., Glazer, Robert D., Pettyjohn, Frank S., Coenen, P. D. M., Zhao, Yanxing, Grosso, Amie
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Antihypertensive Agents - administration & dosage
Antihypertensive Agents - adverse effects
Antihypertensive Agents - therapeutic use
Blood pressure control
Combination therapy
Diuretics - administration & dosage
Diuretics - adverse effects
Diuretics - therapeutic use
Double-Blind Method
Drug Combinations
Female
Humans
Hydrochlorothiazide
Hydrochlorothiazide - administration & dosage
Hydrochlorothiazide - adverse effects
Hydrochlorothiazide - therapeutic use
Hypertension - drug therapy
Male
Middle Aged
Severe hypertension
Tetrazoles - administration & dosage
Tetrazoles - adverse effects
Tetrazoles - therapeutic use
Treatment Outcome
Valine - administration & dosage
Valine - adverse effects
Valine - analogs & derivatives
Valine - therapeutic use
Valsartan
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Objective: Most patients with severe hypertension are at high risk for cardiovascular events and require prompt blood pressure (BP)-lowering and combination therapy to achieve BP goals. This study evaluated the therapeutic efficacy and tolerability of initial treatment with the combination of valsartan and hydrochlorothiazide (HCTZ) compared with valsartan monotherapy in patients with severe hypertension. Research design and methods: This was a 6-week, randomized, double-blind, multicenter, forced titration study that compared initial therapy with the combination of valsartan/HCTZ 160/12.5 mg (force titrated to 160/25 mg after 2 weeks and to 320/25 mg after 4 weeks) to monotherapy with valsartan 160 mg (force titrated to 320 mg after 2 weeks and sham-titrated to 320 mg after 4 weeks). Eligible patients were 18–80 years old with severe essential hypertension (mean sitting diastolic BP ≥ 110 mmHg and
ISSN:0300-7995
1473-4877
DOI:10.1185/03007990802271946